It has been known for many years that systemic administration of certain vasoactive drugs can result in selective reductions in tumour blood flow (Algire & Legallais, 1951; Cater et al., 1962; Cater et al., 1963; Knapp et al., 1985) . One of the most effective agents in reducing blood flow to tumours without affecting normal tissue blood flow is 5-hydroxytryptamine (Cater et al., 1962; Cater et al., 1963; Cater et al., 1965 : Knapp et al., 1985 .
The rationale for the present study was to evaluate if this selective reduction in tumour blood flow and thus oxygenation reported after administration of 5-HT could be exploited therapeutically using the 1-substituted 2-nitroimidazole RSU-1069. This compound has been shown to be selectively toxic to hypoxic cells both in vitro (Stratford et al., 1986a) and in vivo (Chaplin et al., 1986) .
Materials and methods
Mice and tumour All experiments were performed using the Lewis lung carcinoma growing in female C57B1/6 mice (Charles River Inc.). The tumour has been maintained by inoculation of tumour brei into the gastrocnemius muscle. After 10 consecutive passages, the tumour line was discarded and subsequently renewed from frozen stock. Tumours required for experimentation were derived by s.c.
injection of 105 to 106 viable tumour cells (obtained by enzymatic digestion) over the sacral region of the back and were used when the tumours attained a mean diameter of 6-8 mm.
Preparation of tumour cell suspension Tumours were excised 18-20 h after drug treatment. For each treatment group, 2-4 mice each bearing one tumour were used. Following excision, the tumours were pooled, washed with PBS chopped using crossed scalpels and weighed. The resulting fragments after being washed with PBS were disaggregated by gentle agitation for 30 min with an enzyme cocktail of trypsin (0.1%), DNAse (0.05%) and collagenase (0.02%). The resulting cell suspension was filtered through polyester mesh (50 jum pore size), centrifuged and the cell pellet resuspended in media. Cell suspensions were subsequently counted on a haemocytometer enabling tumour cell yield to be ascertained. The mean cell yield for untreated tumours in the series of experiments was 3.2 x 107 g1 of tissue (s.d. 1.0 x 107).
Measurement of tumour response a) Soft agar clonogenic assay. This assay has been described in detail previously (Courtenay, 1976 Results Figure 1 shows the response of the Lewis lung carcinoma to various doses of RSU-1069. It can be seen that RSU-1069 is cytotoxic to this tumour with a surviving fraction of 2 x 10 1 being obtained after administration of 0.1mgg-'. The effect of 5-HT on tumour cell survival is shown in Figure 2 . No significant cytotoxicity is observed after administration of 5-HT alone in doses up to 5 mg kg-'.
In the initial studies involving the administration of both RSU-1069 and 5-HT, the importance of drug scheduling was investigated by administering 5-HT (5mgkg-') at various times from 3h before to 4 h after RSU-1069 (0.1 mg g-'). From the results obtained (Figure 3 ), it can be seen that the maximum tumour cell kill is observed when 5-HT is given after RSU-1069. Based on the results shown in Figure 3 , a schedule of administering 5-HT 60min after RSU-1069 was chosen as being optimum for achieving tumour cell kill in the present system and was used in all subsequent studies. Figure 5 . It can be clearly seen that the potentiation increases with increasing doses of 5-HT, however, these increases appear to become maximal at a 5-HT dose of 2mgkg-.
Growth delay studies are shown in Figure 6 . It can be seen that the growth delay observed when 5-HT (5mgkg-') is administered 60min after RSU-1069 (0.1mgg-1) is greater than when either agent is administered alone. The growth delay values (±s.e.) obtained in this study were 1.9 (±1.1), 0.9 (±1.3) and 5.6 (±0.8) for RSU-1069 alone, 5-HT alone and 5-HT+RSU-1069 respectively. Although these tumour studies clearly indicate that 5-HT can pontentiate the tumour cytotoxicity of the hypoxic cell cytotoxin RSU-1069, such an effect will only be therapeutically beneficial if similar potentiation of systemic toxicity does not occur. In order to assess systemic toxicity, the LD5oI7d of RSU-1069 was determined both when administered alone and when administered 60min before 5-HT (5mgkg-1). It can be seen from the results shown in Table I that 5-HT does not alter the LD50/7d of RSU-1069. Thus, the potentiation of RSU-1069 cytotoxicity by 5-HT is likely to be tumour-specific.
Discussion
The basis of selective toxicity is to exploit differences that exist between the normal host cell population and the 'invading' cell population. To date most of the therapies used in cancer treatment are designed to exploit subtle differences in cellular biochemistry and proliferation kinetics that exist between normal and malignant cells. With the exception of hyperthermia little attention has been focussed on utilising the physiological differences between normal and tumour tissue. In the present study, we have evaluated the effect of combining a drug known to selectively reduce tumour blood flow (and thus oxygen delivery) with a drug known to be preferentially toxic to cells at reduced oxygen tensions.
The results in Figure 3 clearly indicate that 5-HT can pontentiate the tumour cytotoxicity of RSU-1069. However, the level of potentiation seen is dependent on the scheduling of the two agents. Little or no potentiation being observed if 5-HT is administered before RSU-1069, whereas if 5-HT is administered after RSU-1069 significant potentiation of tumour cytotoxicity is seen. The absence of potentiation when 5-HT is administered prior to RSU-1069 probably reflects the fact that a 5-HT induced reduction in tumour blood flow both at the time of and immediately after RSU-1069 administration would reduce the amount of RSU-1069 reaching the tumour. It has been reported that peak plasma levels of RSU-1069 after i.p. delivery occur within 5min of injection and then decrease with a half-life of 22min (Workman & Walton, 1984) . Thus any reduction in tumour blood flow in the first 30min after administration of RSU-1069 would dramatically reduce the tumour exposure to this drug and hence cytotoxicity. The maximum tumour cytotoxicity was observed in the present study if 5-HT was administered 1-4h after RSU-1069. The fact that 5-HT can potentiate tumour cytotoxicity when administered 4h after RSU-1069, at which time blood levels of RSU-1069 would be negligible (Workman & Walton, 1984) indicates that any 5-HT alteration of RSU-1069 pharmacokinetics does not contribute to the potentiation of tumour cytotoxicity seen in the present study. The fact that RSU-1069 can bind to aerobic cells and render them susceptible to cell killing during a period of subsequent hypoxia (Stratford et al., 1986b) may explain why potentiation of RSU-1069 tumour cytotoxicity is seen when 5-HT is administered several hours afterwards.
Although the results obtained in the time course study (Figure 3 ) demonstrate that 5-HT can potentiate the cytotoxicity effects of a relatively high dose of RSU-1069, i.e. 0.1 mgg-1, it is important to know if this effect can be observed with lower possibly clinically achievable doses of RSU-1069. It can be seen from the data shown in Figure 4 that 5-HT (5mgkg-1) can potentiate the tumour cytotoxicity of RSU-1069 over a range of RSU-1069 doses from 0.01 to 0.15mgg-. The potentiation appears to be dose modifying over the RSU-1069 dose range studied giving an enhancement ratio of -4.0. The importance of 5-HT dose on the potentiation observed is shown in Figure 5 . It can be seen that potentiation increases with increasing doses of 5-HT up to 2 mg kg-1. However, increasing the dose above this does not provide any significant increase in potentiation. Such an effect could be explained by the results reported by Cater and colleagues (1963) who showed that 5-HT at a dose of 5 mg kg-1 completely abolished tumour blood flow in their tumour system. If such an effect occurred in the Lewis lung tumour at a 5-HT dose of 2mg kg-1 then increasing the dose of 5-HT would not increase the level of tumour hypoxia and thus no further increase in potentiation of RSU-1069 tumour cytotoxicity would be observed. The potentiation of RSU-1069 tumour cytotoxicity by 5-HT observed using the soft agar assay is also observed using tumour growth delay as the endpoint. Of particular importance are the results shown in Table I . These show than no potentiation of the systemic toxicity of RSU-1069 is observed when 5-HT is administered 60min after RSU-1069.
The present study thus indicates that 5-HT can selectively potentiate the tumour cytotoxicity of the hypoxic cell cytotoxin RSU-1069 which would be consistent with the reports that 5-HT selectively reduces tumour blood flow (Cater et al., 1962 : Cater et al., 1963 Cater et al., 1965; Knapp et al., 1985) . Further studies are now required to investigate the effects of combining agents known to selectively reduce tumour blood flow with drugs which are selectively toxic to hypoxic cells. Kruuv and colleagues (1967) reported that several vasodilators reduced tumour blood flow in their experimental tumour systems. As a result of these findings, the investigators stated that administration of such compounds during radiotherapy or chemotherapy regimes would be unlikely to be of value. However, with the recent development of drugs which are known to be selectively toxic to hypoxic cells Zeman et al., 1986) this statement may no longer be true. Indeed, the combination of drugs known to be toxic to hypoxic cells with those known to selectively reduce tumour oxygenation may well represent a new approach to selective tumour therapy.
